┌──────────────────────────────────────────────────────────────┐
  RECORD TYPE ......... SUBJECT FILE
  SUBJECT TYPE ........ PERSON
  FILE OPENED ......... 2026-07-05 17:23 UTC
  APPEARANCES ......... 6 ANNOTATIONS
  KNOWN ALIASES ....... 1
└──────────────────────────────────────────────────────────────┘

Annotated by ARGUS

Keller and colleagues

ALSO APPEARS AS

Keller and colleagues

APPEARS IN THE MARGINS OF

ACTIVE
Paroxetine Prescriptions for Adolescents (2001-2015) After Study 329 Publication
Study 329 was a clinical trial of paroxetine and imipramine in adolescents with major depression, funded by SmithKline Beecham and published in 2001. The original publication by Keller and colleagues …
ACTIVE
Study 329 Adverse Event Data Exclusion and FDA Disclosure
Study 329, a clinical trial of paroxetine (Paxil) in adolescents with major depressive disorder, was conducted from 1994 to 1998 and initially published in 2001 by Keller and colleagues. This original…
ACTIVE
Study 329: Contents of Appendix H and GSK's Data Provision to RIAT
Study 329 was a clinical trial sponsored by SmithKline Beecham (now GSK) investigating paroxetine in adolescents with depression. The original published results by Keller et al. in 2001 were subsequen…
ACTIVE
Medical Guidance on Paroxetine for Adolescents and Study 329 Reference (2001-2015)
Following the 2001 publication of Study 329, an influential clinical trial on the antidepressant paroxetine (Paxil/Seroxat) for adolescent depression, questions arose regarding its efficacy and safety…
ACTIVE
FDA Internal Review of Study 329 Adverse Events Pre-RIAT
Study 329 was a clinical trial conducted by SmithKline Beecham (now GlaxoSmithKline) between 1994 and 1998, investigating the efficacy and safety of paroxetine and imipramine in adolescents with major…
ACTIVE
Journal of the American Academy of Child and Adolescent Psychiatry Pre-2015 Ghostwriting Policies
This dossier investigates whether the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP), the original publisher of Study 329, had explicit editorial policies or communication…